6/105 sources · 4 publishersUpdated Oct 19, 20:18 UTC
CRISPR Therapeutics appoints A.J. Silver as new CFO after Raju Prasad departs
+3 new sources since this summary was written
CRISPR Therapeutics announced that Chief Financial Officer Raju Prasad will leave the company to pursue external opportunities. Effective immediately, Senior Vice President of Finance A.J. Silver will assume the CFO role. The transition was confirmed by CEO Samarth Kulkarni in a company release.
Why it matters
The change in chief financial officer could influence the company’s financial strategy and its communication with investors, as noted by the company’s statement that the transition is effective today.
Key facts
- 1Raju Prasad, Ph.D., will step down as CFO to pursue external opportunities. stocktitan.net
- 2A.J. Silver, the Senior Vice President of Finance, will succeed Prasad as CFO effective today (Oct. 19, 2026). stocktitan.net
- 3Silver has served as Senior Vice President of Finance since January 2025 and joined CRISPR Therapeutics in October 2018. stocktitan.net
- 4The CFO change was announced by the company on Oct. 19, 2026. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.